AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00

AnaptysBio (NASDAQ:ANAB) had its price target increased by equities researchers at Guggenheim from $75.00 to $90.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price objective would indicate a potential upside of 155.90% from the stock’s previous close.

Several other brokerages also recently weighed in on ANAB. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of AnaptysBio in a research report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Wedbush restated an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research report on Thursday, September 26th. Finally, Truist Financial upped their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Stock Up 0.5 %

NASDAQ ANAB traded up $0.19 on Monday, hitting $35.17. 83,983 shares of the stock were exchanged, compared to its average volume of 322,603. AnaptysBio has a fifty-two week low of $13.36 and a fifty-two week high of $41.31. The company has a market cap of $960.81 million, a PE ratio of -5.68 and a beta of -0.29. The company has a 50-day moving average price of $35.42 and a 200-day moving average price of $29.39.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The firm had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. As a group, equities research analysts predict that AnaptysBio will post -6.84 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other AnaptysBio news, insider Eric J. Loumeau sold 8,720 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the transaction, the insider now directly owns 7,020 shares in the company, valued at approximately $279,536.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC lifted its holdings in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. Duncan Williams Asset Management LLC purchased a new position in shares of AnaptysBio during the 3rd quarter worth about $282,000. SG Americas Securities LLC purchased a new position in shares of AnaptysBio during the 3rd quarter worth about $405,000. Algert Global LLC lifted its holdings in shares of AnaptysBio by 11.8% during the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 1,078 shares during the period. Finally, Frazier Life Sciences Management L.P. lifted its holdings in shares of AnaptysBio by 140.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after acquiring an additional 1,265,891 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.